



MC-2751

**LABORATORY REPORT**

<b>NAME</b> : MR.SI0014	<b>REFERRED BY</b> : SELF	<b>VISIT NO</b> : VAMP26147919
<b>AGE</b> : 40Y 0M 0D	<b>ZERO TARIFF CLIENT CODE</b>	<b>COLLECTED ON</b> : 21-04-2026 10:00
<b>GENDER</b> : Male	<b>LAB MR#</b> : AAMP01479198	<b>RECEIVED ON</b> : 21-04-2026 18:08
<b>OP / IP / DG #</b> :		<b>APPROVED ON</b> : 22-04-2026 20:00
		<b>REPORT STATUS</b> : Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**SEROLOGY AND IMMUNOLOGY**

**Anti Nuclear Antibody (ANA) Profile - Immuno Blot (Extractable Nuclear Antigens/ENA) (Serum)**

dsDNA	Negative	Negative
Nucleosomes	Negative	Negative
Sm	Negative	Negative
Histones	Negative	Negative
PCNA	Negative	Negative
Ribosomal-P Protein (PO)	Negative	Negative
SS-A	Negative	Negative
Ro-52	Negative	Negative
SS-B	Negative	Negative
CENP B	Negative	Negative
Scl-70	Negative	Negative
nRNP/Sm	Negative	Negative
AMA-M2(M2)	Negative	Negative
Jo-1	Negative	Negative
PM - SCL (PM)	Negative	Negative
Mi-2	Negative	Negative
Ku	Negative	Negative

**Interpretation:**

Antigen	Disease	Prevalance of autoantibodies
nRNP/Sm	MCTD	95-100%
	SLE	15-40%
	SS	2-12%
	PM/DM	12-16%
Sm (Smith antigen)	SLE	5-40%
SS-A (Ro)	SS	40-95%
	SLE	22-60%
	Neonatal lupus	95-100%
Ro-52	SS or SLE	40-95%, 40-60%
SS-B (La)	SS	40-95%
	SLE	10-20%
	Neonatal lupus	75%





MC-2751

LABORATORY REPORT

NAME	: MR.SI0014	REFERRED BY	: SELF	VISIT NO	: VAMP26147919
AGE	: 40Y 0M 0D	ZERO TARIFF CLIENT CODE		COLLECTED ON	: 21-04-2026 10:00
GENDER	: Male	LAB MR#	: AAMP01479198	RECEIVED ON	: 21-04-2026 18:08
OP / IP / DG #	:			APPROVED ON	: 22-04-2026 20:00
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
Scl-70	SS	25-75%	
Pm-Scl	SS	10-20%	
	PM-SS Overlap synd	18%	
Jo-1	PM/DM	25-35%	
Centromeres	SS limited form	80-95%	
	SS diffuse form	8%	
	PBC	10-30%	
dsDNA	SLE	40-90%	
Nucleosomes	SLE	40-70%	
Histones	DLE	95-100%	
	SLE	50%	
	RA	15-50%	
Ribosomes P-protein	SLE	10%	
AMA-M2	PBC	96%	

NOTE:

- Sample screening dilution - 1:101
- Immunoblot assay detects selected 14 ANAs which are most important & clinically relevant. However, in general, ANA includes many autoantibodies directed towards many nuclear (DNA & nucleoplasm) & cytoplasmic antigens, which are maximally screened & detected by using Hep-2 cells in indirect immunofluorescence method, but, not all of these are always clinically relevant antibodies.
- There is a possibility of patients having ANA positive by indirect immunofluorescence method but negative results on immunoblot. Also note that Immunoblot assay is more sensitive for Ro52/SSa, Scl70, while poorly sensitive for DsDNA, hence such patients require further follow up with monospecific ELISAs based on clinical correlation & diagnosis.
- For weak Positive results repeat testing after 4-6 weeks or further testing with Monospecific Nuclear Antigens or Panels for confirmation of specific Autoantibodies is suggested.





LABORATORY REPORT

NAME	: MR.SI0014	REFERRED BY	: SELF	VISIT NO	: VAMP26147919
AGE	: 40Y 0M 0D	ZERO TARIFF CLIENT CODE		COLLECTED ON	: 21-04-2026 10:00
GENDER	: Male	LAB MR#	: AAMP01479198	RECEIVED ON	: 21-04-2026 18:08
OP / IP / DG #	:			APPROVED ON	: 22-04-2026 20:00
				REPORT STATUS	: Final Report



Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

Dr. G. Amitha  
MBBS, MD (MICROBIOLOGY)  
Consultant Microbiologist

Disclaimer:

1. All results released pertain to the specimen as received by the lab for testing and under the assumption that the patient indicated or identified on the bill/test requisition form is the owner of the specimen.
2. Clinical details and consent forms, especially in Genetic testing, histopathology, as well as wherever applicable, are mandatory to be accompanied with the test requisition form. The non-availability of such information may lead to delay in reporting as well as misinterpretation of test results. The lab will not be responsible for any such delays or misinterpretations thereof.
3. Test results are dependent on the quality of the sample received by the lab. In case the samples are preprocessed elsewhere (e.g., paraffin blocks), results may be compromised.
4. Tests are performed as per the schedule given in the test listing and in any unforeseen circumstances, report delivery may be affected.
5. Test results may show inter-laboratory as well as intra-laboratory variations as per the acceptable norms.
6. Genetic reports as well as reports of other tests should be correlated with clinical details and other available test reports by a qualified medical practitioner. Genetic counselling is advised in genetic test reports by a qualified genetic counsellor, medical practitioner or both.
7. Samples will be discarded post processing after a specified period as per the laboratory's retention policy. Kindly get in touch with the lab for more information.
8. If accidental damage, loss, or destruction of the specimen is not attributable to any direct or negligent act or omission on the part of Ampath Labs or its employees, Ampath shall in no event be liable. Ampath lab's liability for a lack of services, or other mistakes and omissions, shall be restricted to the amount of the patient's payment for the pertinent laboratory services.

